AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 183.11B +0.6% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 23.45 |
| Forward PE | 14.74 |
| Dividend | 2.39 (2.02%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 2,049,945 |
| Open | 11,858 |
| Previous Close | 11,806 |
| Day's Range | 11,832 - 12,140 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 15,643.72 (+29.82%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,644p, which is an increase of 29.82% from the latest price.
News
The Key to Pharma M&A: Never Shopping Hungry
Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.
PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend
Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee says Get our breaking news email , free app or daily news podcast The fede...
Information Services Group, Inc.: ISG Event to Spotlight Strategies for the AI-Driven Autonomous Enterprise
Leaders from Lloyds Banking Group, NatWest, Ogilvy, AstraZeneca, Diageo, Reckitt, Carlsberg, Shell and more to join ISG AI Impact Summit London Information Services Group (ISG) (Nasdaq: III), a gl...
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch
AZN Looks 12.9% Undervalued on GF Value⢠Amid Dividend Sustainability
AZN Looks 12.9% Undervalued on GF Value⢠Amid Dividend Sustainability
AstraZeneca to discontinue eVOLVE-Lung02 Phase III trial
AstraZeneca (AZN) announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line therapy compared to pembrolizumab and chemo...
AZN Looks 12.9% Undervalued on GF Value⢠Amid Strong Dividend Profile
AZN Looks 12.9% Undervalued on GF Value⢠Amid Strong Dividend Profile
AZN Looks 12.9% Undervalued on GF Value⢠with Solid Dividend Fundamentals
AZN Looks 12.9% Undervalued on GF Value⢠with Solid Dividend Fundamentals
AstraZeneca announces results from DESTINY-Lung04 trial of Enhertu
Results from the DESTINY-Lung04 Phase III trial showed Enhertu demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus global standard of car...
AstraZeneca announces results from Phase III trial of Tagrisso, savolitinib
Positive high-level results from the Saffron Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free su...
AstraZeneca announces results from Phase III trial of Tagrisso, savolitinib
Positive high-level results from the Saffron Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free su...
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically ...
FTSE 100 set to snap six-day losing streak as miners gain
Britain's FTSE 100 edged higher on Monday, on track to end six straight days of losses, as strength in mining stocks, AstraZeneca and Rolls-Royce offset broader caution ahead of this week's UK inflati...
AstraZeneca Discontinues Phase 3 EVOLVE-Lung02 Trial Of Volrustomig In Non-small Cell Lung Cancer
(RTTNews) - AstraZeneca PLC (AZN), on Monday said it is discontinuing the Phase 3 eVOLVE-Lung02 trial evaluating Volrustomig plus chemotherapy as a first-line treatment for patients with metastatic no...
AZN Looks 12.9% Undervalued on GF Value⢠Amid Solid Dividend Fundamentals
AZN Looks 12.9% Undervalued on GF Value⢠Amid Solid Dividend Fundamentals
AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer
(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday positive results from SAFFRON Phase III trial, with Tagrisso (osimertinib) plus Orpathys (savolitinib) demonstrating statis...
AstraZeneca ditches lung cancer treatment trial
The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.
AstraZeneca To Cease EVOLVE-Lung02 Phase III Trial Of Volrustomig + Chemotherapy In MNSCLC
(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that it is discontinuing the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lu...
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review
The decision was based on the recommendation of the Independent Data Monitoring Committee, which said volrustomig plus chemotherapy was unlikely to reach primary endpoints.
AstraZeneca PLC: Enhertu improved PFS in 1L HER2m lung cancer
17 August 2026 Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-smal...
AstraZeneca to discontinue late-stage lung cancer trial for volrustomig
AstraZeneca on Monday said it is discontinuing a late stage trial that tested volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer.
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused ...
Sarah Ketterer's Top Q2 2026 Move: AstraZeneca PLC at a 3.92% Portfolio Impact
Sarah Ketterer's Top Q2 2026 Move: AstraZeneca PLC at a 3.92% Portfolio Impact
AZN Looks 12.3% Undervalued on GF Value⢠Amid Dividend Strength and Insider Selling
AZN Looks 12.3% Undervalued on GF Value⢠Amid Dividend Strength and Insider Selling
Investor backlash killed AstraZeneca, Bristol Myers tie-up, FT reports
AstraZeneca (AZN) CEO Pascal Soriot had been quietly pursuing a transformative deal and held serious talks with Bristol Myers (BMY) over a potential mostly stock-based acquisition at a premium, despit...